By Nanomi
Our proprietary PrecisionSphere™ platform helps companies extend the lifecycle of products whether in development or already on the market by transforming them into longer acting formulations. This supports improved patient convenience and unlocks new market opportunities for established therapies. Why partners choose PrecisionSphere™ - Consistent, controlled release supporting treatment durations from weeks to months - Uniform particle size, shape, and biological properties, enabling predictable and reliable drug performance - Improved injectability: a well-controlled particle size and size distribution allow for smaller needles and reduce adverse injection effects. - De-risked through regulatory validation Nanomi achieved FDA approval for a lead long acting injectable product using the PrecisionSphere™ technology, demonstrating commercial readiness of the platform.
